Organicell reports no safety events in Phase 1/2a studies of Zofin; plans Phase 2 in 2024

Zeo ScientifiX, Inc.

No therapy-related safety events or significant adverse events across three Phase 1/2a studies with over 20 Zofin-treated patients.
Studies include knee osteoarthritis, moderate-to-severe COVID-19, and long-haul COVID-19 (expected completion October 2023).
Company plans to initiate larger Phase 2 studies for multiple chronic conditions in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.